stock ticker hero image

Investor relations

Our science-led strategy is key to delivering long-term value for patients, employees and shareholders.

NYSE: MRK
March 28, 2023 12:40 pm ET
Delayed at least 20 minutes

View stock information

Latest news, events & financials

View all

Our pipeline shows our relentless pursuit of the next breakthrough.

Phase II programs
83
Phase III programs
30
Under review
3
Illustration of leaders speaking on stage

Our leadership

Our deep bench of talent has the knowledge, commitment and expertise to successfully execute on our innovation strategy.

women harvesting tea leaves with basket

Environmental, Social & Governance (ESG)

Supporting the future of our business and the health and well-being of patients, people and communities around the world.

Download our 2021/2022 ESG Progress Report

We're led by our science

We follow the science to our next breakthrough, leaving no stone unturned.

View our stories
Innovation

Merck’s Q4 and full-year 2022 earnings report

Merck’s (NYSE: MRK) Q4 and full-year 2022 results reflect sustained strong revenue growth. The company announced Q4 worldwide sales of $13.8 billion, an increase of 2% from Q4 2021. Full-year 2022 worldwide sales were $59.3 billion, an increase of 22% from full year 2021. “2022 was an exceptional year for Merck, which is a testament […]

Read more

Next: Merck’s Q4 and full-year 2022 earnings report

Innovation

Celebrating the opening of our latest state-of-the-art facility

The FLEx Center will help us continue to harness the power of leading-edge science with agility

Read more

Next: Celebrating the opening of our latest state-of-the-art facility

Innovation

Why we’re expanding and investing in our research and discovery efforts

Our commitment to innovation helps ensure a brighter future for patients everywhere

Read more

Next: Why we’re expanding and investing in our research and discovery efforts

Innovation

Merck’s Q4 and full-year 2022 earnings report

Merck’s (NYSE: MRK) Q4 and full-year 2022 results reflect sustained strong revenue growth. The company announced Q4 worldwide sales of $13.8 billion, an increase of 2% from Q4 2021. Full-year 2022 worldwide sales were $59.3 billion, an increase of 22% from full year 2021. “2022 was an exceptional year for Merck, which is a testament […]

Read more

Next: Merck’s Q4 and full-year 2022 earnings report

Innovation

Celebrating the opening of our latest state-of-the-art facility

The FLEx Center will help us continue to harness the power of leading-edge science with agility

Read more

Next: Celebrating the opening of our latest state-of-the-art facility

Innovation

Why we’re expanding and investing in our research and discovery efforts

Our commitment to innovation helps ensure a brighter future for patients everywhere

Read more

Next: Why we’re expanding and investing in our research and discovery efforts

Previous
Next

Unsubscribe from email alerts

Contact us banner image
For questions, please contact our team.

Contact investor relations